PerkinElmer makes appointment
This article was originally published in Scrip
PerkinElmer(US) has appointed Dr Alan Fletcher vice-president of bio-discovery business development, in its life and analytical sciences business. He will be responsible for developing partnerships and introducing new technologies. Dr Fletcher joins from GE Healthcare were he held a number of positions in its life science and discovery systems business units.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.